
The SERENA-6 Design: Switching Therapy Before the Scan Changes
Dr. Hundal walks through SERENA-6: ctDNA monitoring on CDK4/6 + AI, randomization at emergent ESR1 detection, and the 16- vs 9-month PFS result.
Premji:Welcome to Between the Lines with CancerNetwork. In the next few minutes, we’ll walk through a study we think has the potential to influence clinical practice — what it shows, and what it means for the patients in front of us. Let’s get into it. I’m Sarah Premji, assistant director of breast cancer research at Sarah Cannon Research Institute in Nashville, Tennessee. I’m joined by my esteemed colleague, Dr. Hundal.
Hundal:Thanks, Sarah. I’m Jasmin Hundal — I recently graduated from the hematology/oncology fellowship at the Cleveland Clinic.
Premji:Thanks for being here. Today we’re diving into SERENA-6 — a very hot topic. Can you walk us through the trial design?
Hundal:Sure. SERENA-6 was a uniquely designed clinical trial. We know that patients with hormone receptor–positive, HER2-negative advanced breast cancer develop endocrine resistance in up to 40% of cases, and on a CDK4/6 inhibitor plus aromatase inhibitor (AI) the median time to an emergent ESR1 mutation is roughly 6 months. The question SERENA-6 asked was whether catching molecular progression — the appearance of an ESR1 mutation on ctDNA — before radiographic progression would change outcomes for our patients.
Hundal:The study enrolled patients with advanced breast cancer on a CDK4/6 inhibitor plus AI for at least 6 months and performed ctDNA measurements every 2 to 3 months until an emergent ESR1 mutation was detected. At that point, patients were randomized 1:1 to camizestrant plus the same CDK4/6 inhibitor versus AI plus the same CDK4/6 inhibitor — control arm. The primary endpoint was median progression-free survival. The regimen has now received accelerated FDA approval.
Hundal:The median PFS was 16 months with camizestrant plus CDK4/6 inhibitor, versus 9 months in the control arm. The PFS2 was 25 months versus 19 months. That is really exciting — we’re seeing a clinically significant improvement. What are your thoughts?
Related to this article







